在中度至重症牛皮中使用deucravacitinib在第52周完全清除皮肤的预测因素的识别:一项前性观察研究
Yohei Takahashi1, Teppei Hagino1, Hidehisa Saeki2
1Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, JPN.
Cureus
|July 17, 2025
概括
年轻的年龄和较低的BMI预测了用deucravacitinib治疗的牛皮患者的完整皮肤清除. 这些因素可以帮助个性化治疗策略,以获得更好的结果.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 德乌克拉维西提尼布是一种有效的口服治疗中度至重度牛皮.
- 并非所有患者在一年后使用deucravacitinib实现完全皮肤清除 (CSC).
- 需要预测基线因素来实现CSC.
研究的目的:
- 为了确定基线人口统计学,临床和实验室因素预测CSC在52周的deucravacitinib治疗.
- 为确定选择患者接受德乌克拉维西提尼布治疗的标准.
主要方法:
- 77名中度至重度牛皮患者的前性单中心研究.
- 患者每天接受6毫克deucravacitinib,每天一次.
- 在52周实现CSC (PASI 0) 的患者和没有实现CSC的患者之间进行了基线因素的比较.
主要成果:
- 77名患者中有15名患者在第52周实现了CSC.
- 获得CSC的人显著年轻 (中位数为55.0岁与67.0岁),BMI较低 (中位数为20.9kg/m2与23.6kg/m2).
- 获得CSC的患者在指甲,头皮和生殖器损伤以及生活质量方面表现得更快.
结论:
- 体重指数 (BMI) 低于22.9kg/m2和年龄低于61岁独立预测52周的CSC成就.
- 这些发现可以帮助早期选择治疗和患者分层.
- 这些预测因素可以促进牛皮的个性化护理策略.
相关概念视频
Clinical Applications of Epidermal Stem Cells
2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Changes in Skin Color: Clinical Perspectives
2.2K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204


